Meta-analysis of the studies including stages III and IV nonsmall cell lung cancer (NSCLC), with their characteristics
| First author [ref. no.] | Method | QS % | Patients n | p53+ % | HR | 95% CI |
| Hayakawa 41 | IHC-;DO-;7 | 58 | 22 | 77 | 0.64 | 0.09–4.39 |
| Kandioler-Eckersberger 46 | PCR-;sequencing | 54 | 24 | 33 | 3.58 | 0.98–13.00 |
| Kawasaki 48 | IHC | 55 | 70 | 60 | 1.60 | 0.99–2.60 |
| Kondo 51 | RT-;PCR-;SSCP | 33 | 19 | 26 | 4.72 | 1.22–18.29 |
| Langendijk 55 | IHC-;DO-;7 | 69 | 65 | 57 | 1.25 | 0.73–2.16 |
| Levesque 59 | ELISA | 63 | 17 | 53 | 4.42 | 0.80–24.43 |
| Mitsudomi 65 | PCR-;SSCP | 53 | 62 | 44 | 2.30 | 1.22–4.32 |
| Murakami 70 | PCR-;DGGE | 63 | 32 | 28 | 2.24 | 0.92–5.44 |
| Nishio 71 | IHC-;DO-;7 | 63 | 21 | 38 | 0.92 | 0.43–1.98 |
| Overall | 58 | 332 | 44 | 1.68 | 1.30–2.18 | |
QS: quality score
p53+: presence of an abnormality of p53
HR: hazard ratio
CI: confidence interval
IHC-;DO-;7: immunohistochemistry with monoclonal antibody DO-;7
PCR: polymerase chain reaction
IHC: immunohistochemistry with antibodies other than DO-;7 or 1801
RT: reverse transcription
ELISA: enzyme-linked immunosorbent assay technique
SSCP: single-strand conformation polymorphism method
DGGE: denaturing gradient gel electrophoresis
Group of NSCLC Stages III–IV, n=9
Chi-;squared statistic for heterogeneity=10.61, 8 degrees of freedom, p=0.22